These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 28601352)

  • 1. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
    Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Sfakianos JP; Cha EK; Iyer G; Scott SN; Zabor EC; Shah RH; Ren Q; Bagrodia A; Kim PH; Hakimi AA; Ostrovnaya I; Ramirez R; Hanrahan AJ; Desai NB; Sun A; Pinciroli P; Rosenberg JE; Dalbagni G; Schultz N; Bajorin DF; Reuter VE; Berger MF; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA
    Eur Urol; 2015 Dec; 68(6):970-7. PubMed ID: 26278805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.
    Petros FG; Choi W; Qi Y; Moss T; Li R; Su X; Guo CC; Czerniak B; Dinney C; McConkey DJ; Matin SF
    J Urol; 2021 Sep; 206(3):548-557. PubMed ID: 33881933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
    Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
    Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.
    Robinson BD; Vlachostergios PJ; Bhinder B; Liu W; Li K; Moss TJ; Bareja R; Park K; Tavassoli P; Cyrta J; Tagawa ST; Nanus DM; Beltran H; Molina AM; Khani F; Miguel Mosquera J; Xylinas E; Shariat SF; Scherr DS; Rubin MA; Lerner SP; Matin SF; Elemento O; Faltas BM
    Nat Commun; 2019 Jul; 10(1):2977. PubMed ID: 31278255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
    Nassar AH; Umeton R; Kim J; Lundgren K; Harshman L; Van Allen EM; Preston M; Dong F; Bellmunt J; Mouw KW; Choueiri TK; Sonpavde G; Kwiatkowski DJ
    Clin Cancer Res; 2019 Apr; 25(8):2458-2470. PubMed ID: 30593515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature.
    Hassler MR; Bray F; Catto JWF; Grollman AP; Hartmann A; Margulis V; Matin SF; Roupret M; Sfakianos JP; Shariat SF; Faltas BM
    Eur Urol; 2020 Aug; 78(2):209-220. PubMed ID: 32571725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy.
    Sfakianos JP; Gul Z; Shariat SF; Matin SF; Daneshmand S; Plimack E; Lerner S; Roupret M; Pal S
    Eur Urol Oncol; 2021 Apr; 4(2):170-179. PubMed ID: 33386276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polypoid urothelial tumor with inverted growth pattern in the renal pelvis: morphologic and molecular characteristics of a unique diagnostic entity.
    Wobker SE; Zhong M; Epstein JI
    Hum Pathol; 2017 Jan; 59():26-33. PubMed ID: 27574810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ANXA10 Expression Is Inversely Associated with Tumor Stage, Grade, and TP53 Expression in Upper and Lower Urothelial Carcinoma.
    Kobayashi G; Hayashi T; Sentani K; Ikeda K; Babasaki T; Shigematsu Y; Sekino Y; Uraoka N; Teishima J; Matsubara A; Hinata N; Oue N
    Pathobiology; 2023; 90(2):94-103. PubMed ID: 35780773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
    Audenet F; Isharwal S; Cha EK; Donoghue MTA; Drill EN; Ostrovnaya I; Pietzak EJ; Sfakianos JP; Bagrodia A; Murugan P; Dalbagni G; Donahue TF; Rosenberg JE; Bajorin DF; Arcila ME; Hechtman JF; Berger MF; Taylor BS; Al-Ahmadie H; Iyer G; Bochner BH; Coleman JA; Solit DB
    Clin Cancer Res; 2019 Feb; 25(3):967-976. PubMed ID: 30352907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.
    Yuan X; Liu C; Wang K; Liu L; Liu T; Ge N; Kong F; Yang L; Björkholm M; Fan Y; Zhao S; Xu D
    Oncotarget; 2016 May; 7(18):25826-35. PubMed ID: 27029078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
    Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinicopathologic characteristics, epigenetic biomarkers and prognosis between renal pelvic and ureteral tumors in upper tract urothelial carcinoma.
    Fang D; He S; Xiong G; Singla N; Cao Z; Zhang L; Li X; Zhou L
    BMC Urol; 2018 Mar; 18(1):22. PubMed ID: 29587736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in genomic profile of high-grade urothelial carcinoma according to tumor location.
    Park CK; Cho NH
    Urol Oncol; 2022 Mar; 40(3):109.e1-109.e9. PubMed ID: 34663543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
    Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
    Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.
    Kim PH; Cha EK; Sfakianos JP; Iyer G; Zabor EC; Scott SN; Ostrovnaya I; Ramirez R; Sun A; Shah R; Yee AM; Reuter VE; Bajorin DF; Rosenberg JE; Schultz N; Berger MF; Al-Ahmadie HA; Solit DB; Bochner BH
    Eur Urol; 2015 Feb; 67(2):198-201. PubMed ID: 25092538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
    Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
    Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis.
    Rizzo A; Mollica V; Santoni M; Massari F
    Clin Genitourin Cancer; 2022 Oct; 20(5):482-487. PubMed ID: 35858936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.